Adamis Pharmaceuticals Corp (NASDAQ:ADMP) has been assigned a consensus broker rating score of 1.50 (Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and one has given a strong buy rating to the company. Adamis Pharmaceuticals’ rating score has declined by 12.8% from three months ago as a result of a number of analysts’ upgrades and downgrades.
Analysts have set a one year consensus price objective of $10.17 for the company and are predicting that the company will post ($0.15) earnings per share for the current quarter, according to Zacks. Zacks has also given Adamis Pharmaceuticals an industry rank of 156 out of 265 based on the ratings given to related companies.
ADMP has been the topic of a number of analyst reports. ValuEngine cut shares of Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 3rd. B. Riley reiterated a “buy” rating and issued a $9.50 target price on shares of Adamis Pharmaceuticals in a research report on Wednesday, October 4th. Zacks Investment Research cut shares of Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 20th. Finally, Maxim Group set a $14.00 target price on shares of Adamis Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, December 5th.
A number of large investors have recently modified their holdings of ADMP. Wells Fargo & Company MN purchased a new position in Adamis Pharmaceuticals in the 2nd quarter worth $169,000. Northern Trust Corp increased its position in shares of Adamis Pharmaceuticals by 5.5% in the second quarter. Northern Trust Corp now owns 51,108 shares of the specialty pharmaceutical company’s stock valued at $266,000 after acquiring an additional 2,686 shares during the period. Vanguard Group Inc. increased its position in shares of Adamis Pharmaceuticals by 22.2% in the second quarter. Vanguard Group Inc. now owns 942,940 shares of the specialty pharmaceutical company’s stock valued at $4,903,000 after acquiring an additional 171,167 shares during the period. EAM Investors LLC purchased a new position in shares of Adamis Pharmaceuticals in the second quarter valued at about $1,221,000. Finally, Virtu KCG Holdings LLC increased its position in shares of Adamis Pharmaceuticals by 103.2% in the second quarter. Virtu KCG Holdings LLC now owns 38,474 shares of the specialty pharmaceutical company’s stock valued at $200,000 after acquiring an additional 19,538 shares during the period. Institutional investors own 16.61% of the company’s stock.
Adamis Pharmaceuticals (NASDAQ:ADMP) traded down $0.03 during midday trading on Friday, hitting $4.43. 364,891 shares of the stock were exchanged, compared to its average volume of 523,601. Adamis Pharmaceuticals has a 52 week low of $2.80 and a 52 week high of $6.45. The company has a quick ratio of 3.79, a current ratio of 3.93 and a debt-to-equity ratio of 0.06.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/01/13/adamis-pharmaceuticals-corp-admp-given-10-17-consensus-target-price-by-analysts.html.
Adamis Pharmaceuticals Company Profile
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Get a free copy of the Zacks research report on Adamis Pharmaceuticals (ADMP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.